Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CCCCOTCMKTS:CHUCNASDAQ:CRBPNASDAQ:EXOZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCCCCC4 Therapeutics$1.51-1.0%$1.49$1.09▼$7.66$106.16M2.931.32 million shs114,937 shsCHUCCharlie's$0.10+0.4%$0.10$0.03▼$0.19$25.87M0.9874,210 shs11,000 shsCRBPCorbus Pharmaceuticals$7.90-1.5%$7.72$4.64▼$61.90$96.76M3.11342,742 shs29,679 shsEXOZeXoZymes$10.78+10.8%$12.65$8.50▼$23.99$90.23MN/A17,118 shs969 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCCCCC4 Therapeutics-1.30%+5.56%+16.92%-13.14%-67.17%CHUCCharlie's+0.40%0.00%+3.22%+87.74%-41.47%CRBPCorbus Pharmaceuticals-7.50%-3.49%+8.97%+45.29%-81.56%EXOZeXoZymes-4.98%-21.21%-30.45%-2.60%+972,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCCCCC4 Therapeutics2.2423 of 5 stars3.32.00.00.02.71.70.6CHUCCharlie's1.0063 of 5 stars0.05.00.00.02.11.70.0CRBPCorbus Pharmaceuticals4.0587 of 5 stars3.61.00.04.72.12.50.6EXOZeXoZymesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCCCCC4 Therapeutics 2.50Moderate Buy$12.00697.34% UpsideCHUCCharlie's 0.00N/AN/AN/ACRBPCorbus Pharmaceuticals 3.10Buy$50.88543.99% UpsideEXOZeXoZymes 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CHUC, EXOZ, CCCC, and CRBP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2025CRBPCorbus PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/7/2025CRBPCorbus PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$65.00 ➝ $58.005/7/2025CRBPCorbus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$60.00 ➝ $56.005/7/2025CRBPCorbus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $40.00(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCCCCC4 Therapeutics$35.58M3.00N/AN/A$3.06 per share0.49CHUCCharlie's$8.49M3.05N/AN/A($0.01) per share-9.95CRBPCorbus PharmaceuticalsN/AN/AN/AN/A$11.69 per shareN/AEXOZeXoZymes$70K1,288.98N/AN/A$1.25 per share8.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCCCCC4 Therapeutics-$105.32M-$1.47N/AN/AN/A-259.60%-45.86%-28.96%7/30/2025 (Estimated)CHUCCharlie's-$4.16M-$0.01N/A∞N/A-48.96%N/A-91.82%8/18/2025 (Estimated)CRBPCorbus Pharmaceuticals-$40.21M-$4.22N/AN/AN/AN/A-36.87%-32.87%8/5/2025 (Estimated)EXOZeXoZymes-$5.86MN/A0.00∞N/AN/AN/AN/AN/ALatest CHUC, EXOZ, CCCC, and CRBP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/29/2025Q4 2024CHUCCharlie'sN/A-$0.01N/A-$0.01N/A$1.78 million5/12/2025Q1 2025EXOZeXoZymesN/A-$0.22N/A-$0.22N/AN/A5/7/2025Q1 2025CCCCC4 Therapeutics-$0.48-$0.37+$0.11-$0.37$3.54 million$7.20 million5/6/2025Q1 2025CRBPCorbus Pharmaceuticals-$1.26-$1.39-$0.13-$1.39N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCCCCC4 TherapeuticsN/AN/AN/AN/AN/ACHUCCharlie'sN/AN/AN/AN/AN/ACRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/AEXOZeXoZymesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCCCCC4 TherapeuticsN/A5.705.70CHUCCharlie'sN/A0.670.19CRBPCorbus PharmaceuticalsN/A11.8211.82EXOZeXoZymesN/A6.526.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCCCCC4 Therapeutics78.81%CHUCCharlie's7.80%CRBPCorbus Pharmaceuticals64.64%EXOZeXoZymesN/AInsider OwnershipCompanyInsider OwnershipCCCCC4 Therapeutics8.73%CHUCCharlie's22.40%CRBPCorbus Pharmaceuticals3.60%EXOZeXoZymesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCCCCC4 Therapeutics15071.01 million64.81 millionOptionableCHUCCharlie's40259.95 million201.72 millionNot OptionableCRBPCorbus Pharmaceuticals4012.24 million11.80 millionOptionableEXOZeXoZymes298.37 millionN/AN/ACHUC, EXOZ, CCCC, and CRBP HeadlinesRecent News About These CompanieseXoZymes Selected as Core Industry Partner in $9M NSF-Funded Initiative to Advance Modular Cell-Free BiomanufacturingJune 26 at 4:18 PM | accessnewswire.comAeXoZymes Increases CEO Compensation PackageJune 20, 2025 | tipranks.comExozymes (NASDAQ:EXOZ) Trading 3.9% Higher - Here's WhyJune 11, 2025 | marketbeat.comeXoZymes Highlights Scalable Biomanufacturing Platform and First Spinout, NCTx, on Grow Everything PodcastMay 16, 2025 | accessnewswire.comAeXoZymes Provides First Quarter 2025 and NCTx Subsidiary Update at 5PM EST TodayMay 12, 2025 | accessnewswire.comAeXoZymes to Host First Quarter 2025 and Subsidiary NCTx Update on Monday May 12, 2025, at 5PM ESTMay 7, 2025 | accessnewswire.comAeXoZymes Launches Subsidiary, NCTx, to Unlock a Promising Compound for Gut and Liver HealthMay 6, 2025 | accessnewswire.comABringing clarity and precision to the cell-free space by introducing exozymesApril 21, 2025 | globenewswire.comBioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grantApril 10, 2025 | globenewswire.comeXoZymes Inc. Reports 2024 Progress and IPO SuccessApril 2, 2025 | tipranks.comeXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCOApril 2, 2025 | globenewswire.comeXoZymes Provides Fourth Quarter and Full Year 2024 UpdateApril 2, 2025 | globenewswire.comeXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025March 26, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCHUC, EXOZ, CCCC, and CRBP Company DescriptionsC4 Therapeutics NASDAQ:CCCC$1.50 -0.02 (-0.99%) As of 11:46 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Charlie's OTCMKTS:CHUC$0.10 +0.00 (+0.40%) As of 09:30 AM EasternCharlie's Holdings, Inc., together with its subsidiaries, formulates, markets, and distributes non-combustible nicotine-related, alternative alkaloid vapor, and hemp-derived vapor and edible products. It sells its products through distributors, specialty retailers, and third-party online resellers in the United States, the United Kingdom, Italy, Spain, New Zealand, Australia, and Canada. Charlie's Holdings, Inc. was founded in 2014 and is headquartered in Costa Mesa, California.Corbus Pharmaceuticals NASDAQ:CRBP$7.90 -0.12 (-1.50%) As of 11:46 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.eXoZymes NASDAQ:EXOZ$10.78 +1.05 (+10.79%) As of 09:30 AM EasterneXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Skyworks Stock Down 16% in 2025, Poised for AI Edge Surge Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Tesla: The Next Month Could Make or Break the Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
